GLSI vs. SKYE, GOSS, SCPH, PRQR, IVA, CAPR, RGLS, CRVO, MCRB, and AEON
Should you be buying Greenwich LifeSciences stock or one of its competitors? The main competitors of Greenwich LifeSciences include Skye Bioscience (SKYE), Gossamer Bio (GOSS), scPharmaceuticals (SCPH), ProQR Therapeutics (PRQR), Inventiva (IVA), Capricor Therapeutics (CAPR), Regulus Therapeutics (RGLS), CervoMed (CRVO), Seres Therapeutics (MCRB), and AEON Biopharma (AEON). These companies are all part of the "pharmaceutical preparations" industry.
Skye Bioscience (NASDAQ:SKYE) and Greenwich LifeSciences (NASDAQ:GLSI) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability, community ranking and risk.
21.1% of Skye Bioscience shares are held by institutional investors. Comparatively, 4.2% of Greenwich LifeSciences shares are held by institutional investors. 0.7% of Skye Bioscience shares are held by insiders. Comparatively, 52.9% of Greenwich LifeSciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Skye Bioscience presently has a consensus price target of $22.50, suggesting a potential upside of 86.41%. Greenwich LifeSciences has a consensus price target of $36.00, suggesting a potential upside of 156.96%. Given Skye Bioscience's higher possible upside, analysts plainly believe Greenwich LifeSciences is more favorable than Skye Bioscience.
Greenwich LifeSciences' return on equity of 0.00% beat Skye Bioscience's return on equity.
In the previous week, Skye Bioscience had 4 more articles in the media than Greenwich LifeSciences. MarketBeat recorded 4 mentions for Skye Bioscience and 0 mentions for Greenwich LifeSciences. Greenwich LifeSciences' average media sentiment score of 0.26 beat Skye Bioscience's score of 0.00 indicating that Skye Bioscience is being referred to more favorably in the media.
Skye Bioscience has a beta of 1.74, suggesting that its stock price is 74% more volatile than the S&P 500. Comparatively, Greenwich LifeSciences has a beta of 1.55, suggesting that its stock price is 55% more volatile than the S&P 500.
Greenwich LifeSciences received 4 more outperform votes than Skye Bioscience when rated by MarketBeat users. However, 100.00% of users gave Skye Bioscience an outperform vote while only 33.33% of users gave Greenwich LifeSciences an outperform vote.
Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Skye Bioscience, indicating that it is currently the more affordable of the two stocks.
Summary
Skye Bioscience beats Greenwich LifeSciences on 8 of the 14 factors compared between the two stocks.
Get Greenwich LifeSciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for GLSI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GLSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Greenwich LifeSciences Competitors List
Related Companies and Tools
